Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avecho Biotechnology Ltd V.AVE


Primary Symbol: AVEFF

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.


OTCPK:AVEFF - Post by User

Bullboard Posts
Post by 93Darkhorse93on Apr 12, 2017 10:08pm
227 Views
Post# 26115879

Q4: 79% Revenue Growth and Over 800% Growth in EBITDA…

Q4: 79% Revenue Growth and Over 800% Growth in EBITDA…Inflection Q!!! now the story has turned back to EBITDA generation with the rig count continuing to rally.  Finally reached that critical sales level where gross margin (including amortization and depreciation) turned positive back positive.
 
Best Q from a EBITDA perspective since Q1 ’15.
 
Looking forward, guidance number was so strong. Management already told you revenue in Q1 is up over 230% at the midpoint of guidance range YoY. (39M -41M) AS well up 28% QoQ which is no coincidence revenue growth has been following rig count growth tick for tick! 
 
Last time sales were at this level gross margin was 15-20% range and EBITDA margins back into the 15% range. Project that out on 2017 on business environment improvement you could be looking at EBITDA of 15M – 20M.  When the market cap at this level is only 34.8M it is one of the cheapest stocks I can find.
 
I have started a position right before Q4 and added aggressively today as the stock should have been trading significantly up yet was essentially flat on what was amazing Q1 guidance and solid Q4 results. Time for management to go out and sell their story and themselves as a new leaner management team and business model starting with institutional investors April 20 at the Richmond Club followed by an investment tour in May.  This is your chance to get in before the big guys for a change.
 
LONG

Bullboard Posts